Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Matthew L. Crawley is active.

Publication


Featured researches published by Matthew L. Crawley.


Journal of Medicinal Chemistry | 2010

Improvement of Physiochemical Properties of the Tetrahydroazepinoindole Series of Farnesoid X Receptor (FXR) Agonists: Beneficial Modulation of Lipids in Primates.

Joseph T. Lundquist; Douglas C. Harnish; Callain Younghee Kim; John F. Mehlmann; Rayomand J. Unwalla; Kristin M. Phipps; Matthew L. Crawley; Thomas Joseph Commons; Daniel M. Green; Weixin Xu; Wah-Tung Hum; Julius E. Eta; Irene Feingold; Vikram S. Patel; Mark J. Evans; KehDih Lai; Lisa Borges-Marcucci; Paige Erin Mahaney; Jay E. Wrobel

In an effort to develop orally active farnesoid X receptor (FXR) agonists, a series of tetrahydroazepinoindoles with appended solubilizing amine functionalities were synthesized. The crystal structure of the previously disclosed FXR agonist, 1 (FXR-450), aided in the design of compounds with tethered solubilizing functionalities designed to reach the solvent cavity around the hFXR receptor. These compounds were soluble in 0.5% methylcellulose/2% Tween-80 in water (MC/T) for oral administration. In vitro and in vivo optimization led to the identification of 14dd and 14cc, which in a dose-dependent fashion regulated low density lipoprotein cholesterol (LDLc) in low density lipoprotein receptor knockout (LDLR(-/-)) mice. Compound 14cc was dosed in female rhesus monkeys for 4 weeks at 60 mg/kg daily in MC/T vehicle. After 7 days, triglyceride (TG) levels and very low density lipoprotein cholesterol (VLDLc) levels were significantly decreased and LDLc was decreased 63%. These data are the first to demonstrate the dramatic lowering of serum LDLc levels by a FXR agonist in primates and supports the potential utility of 14cc in treating dyslipidemia in humans beyond just TG lowering.


Journal of Biological Chemistry | 2006

Structural Insights into the Design of Nonpeptidic Isothiazolidinone-containing Inhibitors of Protein-tyrosine Phosphatase 1B

Paul J. Ala; Lucie Gonneville; Milton Hillman; Mary Becker-Pasha; Eddy W. Yue; Brent Douty; Brian Wayland; Padmaja Polam; Matthew L. Crawley; Erin McLaughlin; Richard B. Sparks; Brian Glass; Amy Takvorian; Andrew P. Combs; Timothy C. Burn; Gregory F. Hollis; Richard Wynn

Structural analyses of the protein-tyrosine phosphatase 1B (PTP1B) active site and inhibitor complexes have aided in optimization of a peptide inhibitor containing the novel (S)-isothiazolidinone (IZD) phosphonate mimetic. Potency and permeability were simultaneously improved by replacing the polar peptidic backbone of the inhibitor with nonpeptidic moieties. The C-terminal primary amide was replaced with a benzimidazole ring, which hydrogen bonds to the carboxylate of Asp48, and the N terminus of the peptide was replaced with an aryl sulfonamide, which hydrogen bonds to Asp48 and the backbone NH of Arg47 via a water molecule. Although both substituents retain the favorable hydrogen bonding network of the peptide scaffold, their aryl rings interact weakly with the protein. The aryl ring of benzimidazole is partially solvent exposed and only participates in van der Waals interactions with Phe182 of the flap. The aryl ring of aryl sulfonamide adopts an unexpected conformation and only participates in intramolecular π-stacking interactions with the benzimidazole ring. These results explain the flat SAR for substitutions on both rings and the reason why unsubstituted moieties were selected as candidates. Finally, substituents ortho to the IZD heterocycle on the aryl ring of the IZD-phenyl moiety bind in a small narrow site adjacent to the primary phosphate binding pocket. The crystal structure of an o-chloro derivative reveals that chlorine interacts extensively with residues in the small site. The structural insights that have led to the discovery of potent benzimidazole aryl sulfonamide o-substituted derivatives are discussed in detail.


Bioorganic & Medicinal Chemistry Letters | 2009

Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR)

John F. Mehlmann; Matthew L. Crawley; Joseph T. Lundquist; Ray Unwalla; Douglas C. Harnish; Mark J. Evans; Callain Younghee Kim; Jay E. Wrobel; Paige Erin Mahaney

Pyrrole[2,3-d]azepines have been identified as potent agonists of the farnesoid X receptor (FXR). Based on the planar X-ray crystal structure of WAY-362450 1 in the ligand binding domain and molecular modeling studies, non-planar reduced compounds were designed which led to agonists that exhibit high aqueous solubility and retain moderate in vitro potency.


Organic Letters | 2009

Efficient, Regioselective Palladium-Catalyzed Tandem Heck-Isomerization Reaction of Aryl Bromides and Non-Allylic Benzyl Alcohols

Matthew L. Crawley; Kristin M. Phipps; Igor Goljer; John F. Mehlmann; Joseph T. Lundquist; John W. Ullrich; Cuijian Yang; Paige Erin Mahaney

An efficient and mild method to couple aryl bromides and activated non-allylic alcohols in a Heck reaction with tandem isomerization to selectively afford high yields of 1,5-diarylalkan-1-ones has been developed. Mechanistic insight was gained through NMR studies of products derived from deuterium-labeled intermediates.


Journal of Medicinal Chemistry | 2005

Structure-Based Design and Discovery of Protein Tyrosine Phosphatase Inhibitors Incorporating Novel Isothiazolidinone Heterocyclic Phosphotyrosine Mimetics

Andrew P. Combs; Eddy W. Yue; Michael J. Bower; Paul J. Ala; Brian Wayland; Brent Douty; Amy Takvorian; Padmaja Polam; Zelda R. Wasserman; Wenyu Zhu; Matthew L. Crawley; James Russell Pruitt; Richard B. Sparks; Brian Glass; Dilip P. Modi; Erin McLaughlin; Lori L. Bostrom; Mei Li; Laurine Galya; Karl F. Blom; Milton Hillman; Lucie Gonneville; Brian G. Reid; Min Wei; Mary Becker-Pasha; Ronald M. Klabe; Reid Huber; Yanlong Li; Gregory F. Hollis; Timothy C. Burn


Journal of Medicinal Chemistry | 2006

Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.

Andrew P. Combs; Wenyu Zhu; Matthew L. Crawley; Brian Glass; Padmaja Polam; Richard B. Sparks; Dilip P. Modi; Amy Takvorian; Erin McLaughlin; Eddy W. Yue; Zelda R. Wasserman; Michael J. Bower; Min Wei; Mark Rupar; Paul J. Ala; Brian M. Reid; Dawn Ellis; Lucie Gonneville; Thomas Emm; Nancy Taylor; Swamy Yeleswaram; Yanlong Li; Richard Wynn; Timothy C. Burn; Gregory F. Hollis; Phillip Liu; Brian Walter Metcalf


Archive | 2005

Tetracyclic inhibitors of Janus kinases

James D. Rodgers; Darius J. Robinson; Argyrios G. Arvanitis; Thomas Maduskuie; Stacey Shepard; Louis Storace; Haisheng Wang; Maria Rafalski; Ravi Kumar Jalluri; Andrew P. Combs; Matthew L. Crawley


Organic Letters | 2006

Regioselective synthesis of substituted pyrroles: efficient palladium-catalyzed cyclization of internal alkynes and 2-amino-3-iodoacrylate derivatives.

Matthew L. Crawley; Igor Goljer; Douglas John Jenkins; John F. Mehlmann; Lisa M. Nogle; Rebecca Dooley; Paige Erin Mahaney


Bioorganic & Medicinal Chemistry Letters | 2007

Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors

Richard B. Sparks; Padmaja Polam; Wenyu Zhu; Matthew L. Crawley; Amy Takvorian; Erin McLaughlin; Min Wei; Paul J. Ala; Lucie Gonneville; Nancy Taylor; Yanlong Li; Richard Wynn; Timothy C. Burn; Phillip C.C. Liu; Andrew P. Combs


Bioorganic & Medicinal Chemistry | 2006

Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: Synthesis and structure–activity relationships of a peptide scaffold

Eddy W. Yue; Brian Wayland; Brent Douty; Matthew L. Crawley; Erin McLaughlin; Amy Takvorian; Zelda R. Wasserman; Michael J. Bower; Min Wei; Yanlong Li; Paul J. Ala; Lucie Gonneville; Richard Wynn; Timothy Burn; Phillip Liu; Andrew P. Combs

Collaboration


Dive into the Matthew L. Crawley's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joseph T. Lundquist

Medical University of South Carolina

View shared research outputs
Top Co-Authors

Avatar

Michael J. Bower

University of Texas Southwestern Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge